Demethylating drugs as novel analgesics for cancer pain

Chi T. Viet, Dongmin Dang, Yi Ye, Kentaro Ono, Ronald R. Campbell, Brian Schmidt

Research output: Contribution to journalArticle

Abstract

Purpose: In this study, we evaluated the analgesic potential of demethylating drugs on oral cancer pain. Although demethylating drugs could affect expression of many genes, we focused on the mu-opioid receptor (OPRM1) gene pathway, because of its role in pain processing. We determined the antinociceptive effect of OPRM1 re-expression in a mouse oral cancer model.

Experimental Design: Using a mouse oral cancer model, we determined whether demethylating drugs produced antinociception through re-expression of OPRM1. We then re-expressed OPRM1 with adenoviral transduction and determined if, and by what mechanism, OPRM1 re-expression produced antinociception. To determine the clinical significance of OPRM1 on cancer pain, we quantified OPRM1 methylation in painful cancer tissues and nonpainful contralateral normal tissues of patients with oral cancer, and nonpainful dysplastic tissues of patients with oral dysplasia.

Results: Wedemonstrated thatOPRM1was methylated in cancer tissue, but not normal tissue, of patients with oral cancer, and not in dysplastic tissues from patients with oral dysplasia. Treatment with demethylating drugs resulted in mechanical and thermal antinociception in the mouse cancer model. This behavioral change correlated with OPRM1 re-expression in the cancer and associated neurons. Similarly, adenoviralmediated OPRM1 re-expression on cancer cells resulted in naloxone-reversible antinociception. OPRM1 reexpression on oral cancer cells in vitro increased β-endorphin secretion from the cancer, and decreased activation of neurons that were treated with cancer supernatant. Conclusion:Our study establishes the regulatory role ofmethylation in cancer pain.OPRM1 re-expression in cancer cells produces antinociception through cancer-mediated endogenous opioid secretion. Demethylating drugs have an analgesic effect that involves OPRM1.

Original languageEnglish (US)
Pages (from-to)4882-4893
Number of pages12
JournalClinical Cancer Research
Volume20
Issue number18
DOIs
StatePublished - Sep 15 2014

Fingerprint

Analgesics
Mouth Neoplasms
Pharmaceutical Preparations
Neoplasms
Endorphins
Cancer Pain
Neurons
mu Opioid Receptor
Naloxone
Methylation
Opioid Analgesics
Research Design
Hot Temperature
Gene Expression
Pain
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Demethylating drugs as novel analgesics for cancer pain. / Viet, Chi T.; Dang, Dongmin; Ye, Yi; Ono, Kentaro; Campbell, Ronald R.; Schmidt, Brian.

In: Clinical Cancer Research, Vol. 20, No. 18, 15.09.2014, p. 4882-4893.

Research output: Contribution to journalArticle

Viet, Chi T. ; Dang, Dongmin ; Ye, Yi ; Ono, Kentaro ; Campbell, Ronald R. ; Schmidt, Brian. / Demethylating drugs as novel analgesics for cancer pain. In: Clinical Cancer Research. 2014 ; Vol. 20, No. 18. pp. 4882-4893.
@article{4d7bd0bc704c4ea48a6773c34016237f,
title = "Demethylating drugs as novel analgesics for cancer pain",
abstract = "Purpose: In this study, we evaluated the analgesic potential of demethylating drugs on oral cancer pain. Although demethylating drugs could affect expression of many genes, we focused on the mu-opioid receptor (OPRM1) gene pathway, because of its role in pain processing. We determined the antinociceptive effect of OPRM1 re-expression in a mouse oral cancer model.Experimental Design: Using a mouse oral cancer model, we determined whether demethylating drugs produced antinociception through re-expression of OPRM1. We then re-expressed OPRM1 with adenoviral transduction and determined if, and by what mechanism, OPRM1 re-expression produced antinociception. To determine the clinical significance of OPRM1 on cancer pain, we quantified OPRM1 methylation in painful cancer tissues and nonpainful contralateral normal tissues of patients with oral cancer, and nonpainful dysplastic tissues of patients with oral dysplasia.Results: Wedemonstrated thatOPRM1was methylated in cancer tissue, but not normal tissue, of patients with oral cancer, and not in dysplastic tissues from patients with oral dysplasia. Treatment with demethylating drugs resulted in mechanical and thermal antinociception in the mouse cancer model. This behavioral change correlated with OPRM1 re-expression in the cancer and associated neurons. Similarly, adenoviralmediated OPRM1 re-expression on cancer cells resulted in naloxone-reversible antinociception. OPRM1 reexpression on oral cancer cells in vitro increased β-endorphin secretion from the cancer, and decreased activation of neurons that were treated with cancer supernatant. Conclusion:Our study establishes the regulatory role ofmethylation in cancer pain.OPRM1 re-expression in cancer cells produces antinociception through cancer-mediated endogenous opioid secretion. Demethylating drugs have an analgesic effect that involves OPRM1.",
author = "Viet, {Chi T.} and Dongmin Dang and Yi Ye and Kentaro Ono and Campbell, {Ronald R.} and Brian Schmidt",
year = "2014",
month = "9",
day = "15",
doi = "10.1158/1078-0432.CCR-14-0901",
language = "English (US)",
volume = "20",
pages = "4882--4893",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Demethylating drugs as novel analgesics for cancer pain

AU - Viet, Chi T.

AU - Dang, Dongmin

AU - Ye, Yi

AU - Ono, Kentaro

AU - Campbell, Ronald R.

AU - Schmidt, Brian

PY - 2014/9/15

Y1 - 2014/9/15

N2 - Purpose: In this study, we evaluated the analgesic potential of demethylating drugs on oral cancer pain. Although demethylating drugs could affect expression of many genes, we focused on the mu-opioid receptor (OPRM1) gene pathway, because of its role in pain processing. We determined the antinociceptive effect of OPRM1 re-expression in a mouse oral cancer model.Experimental Design: Using a mouse oral cancer model, we determined whether demethylating drugs produced antinociception through re-expression of OPRM1. We then re-expressed OPRM1 with adenoviral transduction and determined if, and by what mechanism, OPRM1 re-expression produced antinociception. To determine the clinical significance of OPRM1 on cancer pain, we quantified OPRM1 methylation in painful cancer tissues and nonpainful contralateral normal tissues of patients with oral cancer, and nonpainful dysplastic tissues of patients with oral dysplasia.Results: Wedemonstrated thatOPRM1was methylated in cancer tissue, but not normal tissue, of patients with oral cancer, and not in dysplastic tissues from patients with oral dysplasia. Treatment with demethylating drugs resulted in mechanical and thermal antinociception in the mouse cancer model. This behavioral change correlated with OPRM1 re-expression in the cancer and associated neurons. Similarly, adenoviralmediated OPRM1 re-expression on cancer cells resulted in naloxone-reversible antinociception. OPRM1 reexpression on oral cancer cells in vitro increased β-endorphin secretion from the cancer, and decreased activation of neurons that were treated with cancer supernatant. Conclusion:Our study establishes the regulatory role ofmethylation in cancer pain.OPRM1 re-expression in cancer cells produces antinociception through cancer-mediated endogenous opioid secretion. Demethylating drugs have an analgesic effect that involves OPRM1.

AB - Purpose: In this study, we evaluated the analgesic potential of demethylating drugs on oral cancer pain. Although demethylating drugs could affect expression of many genes, we focused on the mu-opioid receptor (OPRM1) gene pathway, because of its role in pain processing. We determined the antinociceptive effect of OPRM1 re-expression in a mouse oral cancer model.Experimental Design: Using a mouse oral cancer model, we determined whether demethylating drugs produced antinociception through re-expression of OPRM1. We then re-expressed OPRM1 with adenoviral transduction and determined if, and by what mechanism, OPRM1 re-expression produced antinociception. To determine the clinical significance of OPRM1 on cancer pain, we quantified OPRM1 methylation in painful cancer tissues and nonpainful contralateral normal tissues of patients with oral cancer, and nonpainful dysplastic tissues of patients with oral dysplasia.Results: Wedemonstrated thatOPRM1was methylated in cancer tissue, but not normal tissue, of patients with oral cancer, and not in dysplastic tissues from patients with oral dysplasia. Treatment with demethylating drugs resulted in mechanical and thermal antinociception in the mouse cancer model. This behavioral change correlated with OPRM1 re-expression in the cancer and associated neurons. Similarly, adenoviralmediated OPRM1 re-expression on cancer cells resulted in naloxone-reversible antinociception. OPRM1 reexpression on oral cancer cells in vitro increased β-endorphin secretion from the cancer, and decreased activation of neurons that were treated with cancer supernatant. Conclusion:Our study establishes the regulatory role ofmethylation in cancer pain.OPRM1 re-expression in cancer cells produces antinociception through cancer-mediated endogenous opioid secretion. Demethylating drugs have an analgesic effect that involves OPRM1.

UR - http://www.scopus.com/inward/record.url?scp=84907907813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907907813&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-14-0901

DO - 10.1158/1078-0432.CCR-14-0901

M3 - Article

C2 - 24963050

AN - SCOPUS:84907907813

VL - 20

SP - 4882

EP - 4893

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 18

ER -